about
Policies to Mitigate Nonmedical Use of Prescription Medications: How Should Emerging Evidence of Gabapentin Misuse Be Addressed?All-Cause and Drug-Related Medical Events Associated with Overuse of Gabapentin and/or Opioid Medications: A Retrospective Cohort Analysis of a Commercially Insured US Population.VMAT2 Inhibitors for Tardive Dyskinesia-Practice Implications.Predictors of Gabapentin Overuse With or Without Concomitant Opioids in a Commercially Insured U.S. Population.Gabapentin for Off-Label Use: Evidence-Based or Cause for Concern?Gabapentin use, abuse, and the US opioid epidemic: the case for reclassification as a controlled substance and the need for pharmacovigilanceKappa opioid receptor antagonism: Are opioids the answer for treatment resistant depression?Reports of gabapentin and pregabalin abuse, misuse, dependence, or overdose: An analysis of the Food And Drug Administration Adverse Events Reporting System (FAERS)
P50
Q41990378-E2597A93-98A1-473B-B5BD-476BC2735CC9Q44349264-6F8D51DC-3C98-4633-A01B-7B31088F2134Q49888714-8E5C34F4-5580-48D0-A7EF-A3440755D0CDQ52315882-DFA1E169-49D9-49D3-8FCE-2A18F4C4D3B3Q58701953-A2CD30A6-70C9-4DE5-A831-9A2884AD9F51Q58770131-78A3E438-C73B-472D-A249-58948B092C11Q91190618-490286B1-F933-41B8-B57A-2D1973BF8605Q91860885-4E2631D6-9E86-4AC8-8E65-9E594150F95F
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Alyssa M Peckham
@ast
Alyssa M Peckham
@en
Alyssa M Peckham
@es
Alyssa M Peckham
@nl
Alyssa M Peckham
@sl
type
label
Alyssa M Peckham
@ast
Alyssa M Peckham
@en
Alyssa M Peckham
@es
Alyssa M Peckham
@nl
Alyssa M Peckham
@sl
prefLabel
Alyssa M Peckham
@ast
Alyssa M Peckham
@en
Alyssa M Peckham
@es
Alyssa M Peckham
@nl
Alyssa M Peckham
@sl
P106
P21
P31
P496
0000-0002-9638-7005